TrialDiabetes, obesity & metabolism2020

Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).

Esteban Jódar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.